Live
- IPL 2024: SRH opt to bat first against Kolkata in Qualifier 1, Gurbaz replaces Salt
- Google's parent company Alphabet earned over Rs 2.5 lakh per second in Q1
- European Wellness Biomedical Group Bharat Unveils Transformative Healthcare Initiatives in India
- Food regulator finds no trace of ethylene oxide in Indian spices
- JK Tyre clocks 56 pc jump in Q4 net profit, declares dividend of Rs 3.50 per share
- South Korea and US hold talks on defence cost sharing
- Schools shut, hospitals on alert as Pakistan sizzles at 50 degrees
- IPL 2024: Yash Dayal's heroics against CSK will overshadow bad memories of past, says father
- 'Jhoothon Ka Sardar', Congress President Kharge attacks PM Modi in poll-bound Haryana
- CAR T-Cell therapy revolutionised landscape of cancer treatment: Doctors
Centre approves Corbevax as precaution dose
Centre approves Corbevax as precaution dose
Highlights
The Centre on Wednesday approved Biological E's Corbevax as a heterologous precaution dose for adults above 18 years for restricted use with two doses of either Covishield or Covaxin, said a source.
New Delhi: The Centre on Wednesday approved Biological E's Corbevax as a heterologous precaution dose for adults above 18 years for restricted use with two doses of either Covishield or Covaxin, said a source.
According to the source, the Corbevax vaccine will be considered as a precaution dose after completion of six months or 26 weeks from the date of administration of the second dose of either Covaxin or Covishield vaccines.
Meanwhile, India on Wednesday reported 16,047 new Covid-19 cases in the last 24 hours.
In the same period, there were 54 additional deaths, taking the nationwide death toll to 5,26,826.
Next Story
ADVERTISEMENT
